According to the World Health Organization (WHO), lung diseases are the second leading cause of death worldwide, and their significance is expected to increase over the next 20 years. Our company provides clinically relevant in vivo and ex vivo lung disease models, including pulmonary fibrosis and asthma. Our expert scientists utilise their expertise to design and conduct studies tailored specifically to the needs of our clients, supporting respiratory discovery programs effectively.
Our lung fibrosis ex vivo models utilise precision cut pulmonary slices (PCPS), three-dimensional tissue explants derived from human or animal lungs. These models preserve the anatomical architecture and specific features of lung tissue, enabling comparative testing across various experimental conditions. PCPS models closely mimic in vivo conditions, making them invaluable for toxicological and pharmaceutical research, and serving as an effective alternative to traditional animal models in compound screening.
Our asthma in vivo models offer a comprehensive approach to studying this complex and heterogeneous chronic inflammatory disease. We provide two distinct mouse models of house dust mite (HDM)-induced asthma, representing either eosinophilic or mixed-granulocytic asthma. These models enable the profiling of anti-inflammatory candidate compounds against standard-of-care treatments, with administration options including oral, subcutaneous and intranasal routes.
Contact Us
Search